Abstract CT323: Accelerated phase I trial of two schedules of the combination of the PARP inhibitor olaparib and AKT inhibitor AZD5363 using a novel intrapatient dose escalation design in advanced cancer patients

2015 ◽  
Author(s):  
Vasiliki Michalarea ◽  
David Lorente ◽  
Juanita Lopez ◽  
Suzanne Carreira ◽  
Hasina Hassam ◽  
...  
Keyword(s):  
Phase I ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Dose Escalation ◽  
Phase I Trial ◽  
Parp Inhibitor ◽  
Advanced Cancer Patients ◽  
Akt Inhibitor

Final results of a first-in-human phase I trial of PBI-05204, an inhibitor of AKT, FGF-2, NF-Kb, and p70S6K in advanced cancer patients.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 3023-3023 ◽  
Author(s):  
H. A. Henary ◽  
R. Kurzrock ◽  
G. S. Falchook ◽  
A. Naing ◽  
S. L. Moulder ◽  
...  
Keyword(s):  
Phase I ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Phase I Trial ◽  
Advanced Cancer Patients

A phase I trial with recombinant interferon γ (Roussel UCLAF) in advanced cancer patients

1990 ◽  
Vol 32 (1) ◽  
pp. 67-70 ◽  
Author(s):  
François Boue ◽  
Zulay Pastran ◽  
Marc Spielmann ◽  
Thierry Le Chevalier ◽  
Rosana Subirana ◽  
...  
Keyword(s):  
Phase I ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Phase I Trial ◽  
Interferon Γ ◽  
Advanced Cancer Patients ◽  
Recombinant Interferon

Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients

2015 ◽  
Vol 64 (9) ◽  
pp. 1159-1173 ◽  
Author(s):  
Maria Grazia Cusi ◽  
Cirino Botta ◽  
Pierpaolo Pastina ◽  
Maria Grazia Rossetti ◽  
Elena Dreassi ◽  
...  
Keyword(s):  
Phase I ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Thymidylate Synthase ◽  
Phase I Trial ◽  
Advanced Cancer Patients ◽  
Epitope Peptide
Sign in / Sign up

Export Citation Format

Share Document